KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $482.9 million.

  • Regeneron Pharmaceuticals' Depreciation & Amortization (CF) rose 12.33% to $136.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $525.1 million, marking a year-over-year increase of 11.84%. This contributed to the annual value of $482.9 million for FY2024, which is 14.70% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Depreciation & Amortization (CF) of $482.9 million as of FY2024, which was up 14.70% from $421.0 million recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $482.9 million during FY2024, and its lowest value of $235.9 million during FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' Depreciation & Amortization (CF) averaged around $415.1 million, with its median value being $421.0 million (2023).
  • Data for Regeneron Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY grew of 23.32% (in 2023) over the last 5 years.
  • Regeneron Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $235.9 million in 2020, then grew by 21.32% to $286.2 million in 2021, then rose by 19.29% to $341.4 million in 2022, then climbed by 23.32% to $421.0 million in 2023, then rose by 14.70% to $482.9 million in 2024.